CHEP+ Clinical Practice Guidelines Program
CV Risk Reduction in Diabetes (SGLT2 inhibitors/GLP-1 Receptor Agonists in Patients with DM and CVD)
Thursday November 19, 2020 • 3-5PM ET
Presented by: Dr. Sheldon Tobe MD, FRCPC, MScCH (HPTE), FACP, FAHA
Dr. Tobe is a specialist in Hypertension and Nephrology, Division of Nephrology, Sunnybrook Health Sciences Centre, and is the University of Toronto Postgraduate Fellowship Director – Nephrology. He is a Professor in the Faculty of Medicine, University of Toronto and Northern Ontario School of Medicine (NOSM).
LEARNING OBJECTIVES
Upon completion of this case study, participants should be able to:
- Describe the patient who should be treated with an SGLT2i or GLP-1 RA
- Explain the rational for this treatment and the potential benefits
- Describe the steps for initiating and monitoring therapy for patients with diabetes
Accreditation: This Group Learning program has been certified by the Canadian College of Family Physicians for up to 6 Mainpro+ credits for the 2-hour presentation including a practice reflection survey to be completed at 6 weeks post-session.
You will receive an email before the event with the details on how to join using Microsoft Teams Online.
FAQs
• How can I contact the organizer with any questions? To contact the organizer, email: Diane Hua-Stewart at Diane.Hua@sunnybrook.ca / (416) 710-3892.
• To learn more: Please visit the event website: https://www.cchangeguidelines.com/